Insider Trading activities of Crispr Therapeutics Ag insiders.

Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Crispr Therapeutics Ag since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Crispr Therapeutics Ag since year 2005. Table 2 shows the detailed insider transactions of Crispr Therapeutics Ag since 2005. The reporting company's ticker symbol is CRSP. The reporting company's CIK number is 1674416.
The total value of stock buying since 2005 is $31,861,686.
The total value of stock sales since 2005 is $48,270,123.
The total value of stock option exercises since 2005 is $1,068,821.


Table 1. Monthly summaries of insider stock purchases, sales, and option exercises for Crispr Therapeutics Ag (CRSP).
Trading Period Insider Buying Insider Sales Option Exercises
year-month Shares Value Shares Value Shares Value
2018-11 0 $0 80,000 $1,540,000 0 $0
2018-01 593,406 $13,499,986 234,091 $6,234,671 29,000 $364,530
2017-12 0 $0 208,551 $4,152,738 31,000 $243,801
2017-11 0 $0 917,577 $17,376,845 0 $0
2017-09 0 $0 3,853 $78,319 3,853 $6,973
2017-08 0 $0 440,421 $8,543,372 23,414 $42,378
2017-07 0 $0 185,595 $3,175,364 0 $0
2017-06 0 $0 203,355 $3,345,563 46,350 $83,892
2017-05 0 $0 105,502 $1,719,372 103,650 $187,602
2017-04 0 $0 120,302 $2,103,879 77,154 $139,645
2016-10 1,311,550 $18,361,700 0 $0 0 $0

Table 2. Detailed insider stock purchases, sales, and option exercises of Crispr Therapeutics Ag insiders (CRSP)
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2018-11-21 Celgene Corp /de/ (10% Owner) Sale 80,000 19.25 1,540,000
2018-01-16 Dylan-hyde Tyler (Chief Legal Officer) Sale 66,000 28.11 1,855,458
2018-01-16 Dylan-hyde Tyler (Chief Legal Officer) Option Ex 21,000 12.57 263,970
2018-01-05 Bayer Global Investments B.v. (10% Owner) Buy 527,472 22.75 11,999,988
2018-01-05 Emster Kurt Von Buy 65,934 22.75 1,499,998
2018-01-05 Emster Kurt Von Sale 92,337 26.96 2,489,405
2018-01-02 Dylan-hyde Tyler (Chief Legal Officer) Sale 38,000 23.15 879,700
2018-01-02 Dylan-hyde Tyler (Chief Legal Officer) Option Ex 8,000 12.57 100,560
2018-01-02 Emster Kurt Von Sale 37,754 26.75 1,010,108
2017-12-29 Dylan-hyde Tyler (Chief Legal Officer) Sale 30,300 22.48 681,295
2017-12-29 Dylan-hyde Tyler (Chief Legal Officer) Option Ex 15,300 13.50 206,550
2017-12-28 Dylan-hyde Tyler (Chief Legal Officer) Sale 700 21.75 15,225
2017-12-28 Dylan-hyde Tyler (Chief Legal Officer) Option Ex 700 14.43 10,101
2017-12-22 Dylan-hyde Tyler (Chief Legal Officer) Sale 15,000 20.55 308,250
2017-12-22 Woiwode Thomas (Director) Sale 3,059 20.29 62,070
2017-12-22 Bolzon Bradley J Phd (Director) Sale 26,016 20.30 528,228
2017-12-21 Kulkarni Samarth (Chief Executive Officer) Option Ex 15,000 1.81 27,150
2017-12-15 Dylan-hyde Tyler (Chief Legal Officer) Sale 15,000 18.90 283,500
2017-12-04 Celgene Corp /de/ (10% Owner) Sale 30,485 19.47 593,542
2017-12-01 Celgene Corp /de/ (10% Owner) Sale 87,991 19.10 1,680,628
2017-11-30 Celgene Corp /de/ (10% Owner) Sale 12,666 19.04 241,160
2017-11-29 Celgene Corp /de/ (10% Owner) Sale 4,263 19.25 82,062
2017-11-28 Celgene Corp /de/ (10% Owner) Sale 5,080 19.22 97,637
2017-11-27 Woiwode Thomas (Director) Sale 200 20.24 4,047
2017-11-27 Bolzon Bradley J Phd (Director) Sale 200 20.24 4,047
2017-11-27 Celgene Corp /de/ (10% Owner) Sale 27,990 19.75 552,802
2017-11-24 Woiwode Thomas (Director) Sale 1,700 20.21 34,358
2017-11-24 Bolzon Bradley J Phd (Director) Sale 1,507 20.21 30,450
2017-11-24 Celgene Corp /de/ (10% Owner) Sale 26,010 20.00 520,200
2017-11-22 Celgene Corp /de/ (10% Owner) Sale 256,000 19.76 5,058,560
2017-11-20 Celgene Corp /de/ (10% Owner) Sale 158,718 19.02 3,018,816
2017-11-17 Celgene Corp /de/ (10% Owner) Sale 51,282 18.44 945,640
2017-11-16 Celgene Corp /de/ (10% Owner) Sale 105,000 18.39 1,930,950
2017-11-15 Celgene Corp /de/ (10% Owner) Sale 15,000 17.67 265,050
2017-11-14 Celgene Corp /de/ (10% Owner) Sale 14,907 17.19 256,251
2017-11-13 Celgene Corp /de/ (10% Owner) Sale 65,093 17.76 1,156,051
2017-11-10 Celgene Corp /de/ (10% Owner) Sale 10,000 17.28 172,800
2017-11-09 Celgene Corp /de/ (10% Owner) Sale 20,000 17.08 341,599
2017-11-08 Celgene Corp /de/ (10% Owner) Sale 16,875 18.06 304,762
2017-11-07 Celgene Corp /de/ (10% Owner) Sale 23,000 18.54 426,420
2017-11-06 Celgene Corp /de/ (10% Owner) Sale 79,327 18.89 1,498,487
2017-11-03 Celgene Corp /de/ (10% Owner) Sale 22,759 19.10 434,696
2017-09-05 Novak Rodger (Chief Executive Officer) Sale 3,853 20.33 78,319
2017-09-05 Novak Rodger (Chief Executive Officer) Option Ex 3,853 1.81 6,973
2017-08-31 Novak Rodger (Chief Executive Officer) Sale 14,617 20.87 305,071
2017-08-30 Kulkarni Samarth (Chief Business Officer) Sale 4,000 20.00 80,000
2017-08-30 Novak Rodger (Chief Executive Officer) Sale 58,103 20.31 1,179,955
2017-08-30 Novak Rodger (Chief Executive Officer) Option Ex 5,722 1.81 10,356
2017-08-28 Kulkarni Samarth (Chief Business Officer) Sale 23,154 20.09 465,163
2017-08-28 Novak Rodger (Chief Executive Officer) Sale 17,692 20.06 354,919
2017-08-28 Novak Rodger (Chief Executive Officer) Option Ex 17,692 1.81 32,022
2017-08-28 Emster Kurt Von Sale 88,011 19.79 1,741,737
2017-08-25 Emster Kurt Von Sale 14,913 19.52 291,101
2017-08-24 Emster Kurt Von Sale 7,868 19.23 151,301
2017-08-23 Emster Kurt Von Sale 7,035 18.53 130,358
2017-08-22 Emster Kurt Von Sale 10,954 18.53 202,977
2017-08-21 Emster Kurt Von Sale 1,250 18.51 23,137
2017-08-18 Emster Kurt Von Sale 1,900 18.53 35,207
2017-08-17 Emster Kurt Von Sale 13,593 18.74 254,732
2017-08-16 Emster Kurt Von Sale 20,548 19.27 395,959
2017-08-15 Emster Kurt Von Sale 25,586 19.53 499,694
2017-08-14 Emster Kurt Von Sale 29,983 19.64 588,866
2017-08-08 Dylan-hyde Tyler (Chief Legal Officer) Sale 1,313 18.60 24,421
2017-08-08 Emster Kurt Von Sale 19,850 18.71 371,393
2017-08-07 Dylan-hyde Tyler (Chief Legal Officer) Sale 13,210 18.56 245,204
2017-08-07 Emster Kurt Von Sale 15,623 18.53 289,494
2017-08-04 Dylan-hyde Tyler (Chief Legal Officer) Sale 477 18.55 8,848
2017-08-04 Emster Kurt Von Sale 3,068 18.50 56,758
2017-08-03 Emster Kurt Von Sale 47,409 17.77 842,457
2017-08-01 Emster Kurt Von Sale 264 17.50 4,620
2017-07-31 Emster Kurt Von Sale 5,248 17.51 91,871
2017-07-28 Emster Kurt Von Sale 400 17.65 7,059
2017-07-27 Emster Kurt Von Sale 40,912 17.62 721,074
2017-07-26 Emster Kurt Von Sale 23,744 17.63 418,606
2017-07-25 Emster Kurt Von Sale 9,186 17.52 160,938
2017-07-14 Emster Kurt Von Sale 36,230 16.82 609,388
2017-07-13 Emster Kurt Von Sale 33,629 16.87 567,321
2017-07-12 Emster Kurt Von Sale 17,872 16.60 296,675
2017-07-11 Emster Kurt Von Sale 14,120 16.52 233,262
2017-07-05 Emster Kurt Von Sale 4,254 16.26 69,170
2017-06-29 Emster Kurt Von Sale 11,610 16.52 191,797
2017-06-28 Emster Kurt Von Sale 31,592 17.04 538,327
2017-06-27 Emster Kurt Von Sale 33,434 17.43 582,754
2017-06-26 Emster Kurt Von Sale 48,001 16.83 807,856
2017-06-23 Emster Kurt Von Sale 30,841 16.23 500,549
2017-06-22 Novak Rodger (Chief Executive Officer) Sale 10,825 15.37 166,391
2017-06-22 Novak Rodger (Chief Executive Officer) Option Ex 10,825 1.81 19,593
2017-06-22 Emster Kurt Von Sale 1,527 16.21 24,752
2017-06-21 Novak Rodger (Chief Executive Officer) Sale 11,578 15.02 173,843
2017-06-21 Novak Rodger (Chief Executive Officer) Option Ex 11,578 1.81 20,956
2017-06-20 Novak Rodger (Chief Executive Officer) Sale 3,252 15.00 48,786
2017-06-20 Novak Rodger (Chief Executive Officer) Option Ex 3,252 1.81 5,886
2017-06-19 Novak Rodger (Chief Executive Officer) Sale 15,392 15.00 230,880
2017-06-19 Novak Rodger (Chief Executive Officer) Option Ex 15,392 1.81 27,859
2017-06-09 Novak Rodger (Chief Executive Officer) Sale 1,100 15.08 16,583
2017-06-09 Novak Rodger (Chief Executive Officer) Option Ex 1,100 1.81 1,991
2017-06-08 Novak Rodger (Chief Executive Officer) Sale 4,203 15.00 63,045
2017-06-08 Novak Rodger (Chief Executive Officer) Option Ex 4,203 1.81 7,607
2017-05-30 Novak Rodger (Chief Executive Officer) Sale 3,650 15.02 54,830
2017-05-30 Novak Rodger (Chief Executive Officer) Option Ex 3,650 1.81 6,606
2017-05-17 Novak Rodger (Chief Executive Officer) Sale 25,923 16.03 415,571
2017-05-17 Novak Rodger (Chief Executive Officer) Option Ex 25,923 1.81 46,920
2017-05-16 Novak Rodger (Chief Executive Officer) Sale 24,077 16.50 397,294
2017-05-16 Novak Rodger (Chief Executive Officer) Option Ex 24,077 1.81 43,579
2017-05-05 Novak Rodger (Chief Executive Officer) Sale 616 16.93 10,425
2017-05-05 Novak Rodger (Chief Executive Officer) Option Ex 616 1.81 1,114
2017-05-04 Novak Rodger (Chief Executive Officer) Sale 13,191 16.37 215,963
2017-05-04 Novak Rodger (Chief Executive Officer) Option Ex 13,191 1.81 23,875
2017-05-03 Novak Rodger (Chief Executive Officer) Sale 20,269 16.34 331,296
2017-05-03 Novak Rodger (Chief Executive Officer) Option Ex 20,269 1.81 36,686
2017-05-02 Novak Rodger (Chief Executive Officer) Sale 15,924 16.53 263,239
2017-05-02 Novak Rodger (Chief Executive Officer) Option Ex 15,924 1.81 28,822
2017-05-01 Dylan-hyde Tyler (Chief Legal Officer) Sale 1,852 16.61 30,754
2017-04-28 Dylan-hyde Tyler (Chief Legal Officer) Sale 4,912 16.62 81,637
2017-04-27 Dylan-hyde Tyler (Chief Legal Officer) Sale 13,527 16.84 227,794
2017-04-27 Kulkarni Samarth (Chief Business Officer) Sale 2,206 16.78 37,023
2017-04-27 Kulkarni Samarth (Chief Business Officer) Option Ex 2,206 1.81 3,992
2017-04-26 Dylan-hyde Tyler (Chief Legal Officer) Sale 3,200 16.76 53,641
2017-04-26 Kulkarni Samarth (Chief Business Officer) Sale 3,275 16.74 54,816
2017-04-26 Kulkarni Samarth (Chief Business Officer) Option Ex 3,275 1.81 5,927
2017-04-25 Dylan-hyde Tyler (Chief Legal Officer) Sale 4,800 16.87 80,990
2017-04-25 Kulkarni Samarth (Chief Business Officer) Sale 5,115 16.87 86,290
2017-04-25 Kulkarni Samarth (Chief Business Officer) Option Ex 5,115 1.81 9,258
2017-04-24 Dylan-hyde Tyler (Chief Legal Officer) Sale 3,522 16.44 57,898
2017-04-24 Kulkarni Samarth (Chief Business Officer) Sale 3,500 16.46 57,620
2017-04-24 Kulkarni Samarth (Chief Business Officer) Option Ex 3,500 1.81 6,335
2017-04-21 Dylan-hyde Tyler (Chief Legal Officer) Sale 3,010 17.02 51,221
2017-04-21 Kulkarni Samarth (Chief Business Officer) Sale 3,000 17.01 51,033
2017-04-21 Kulkarni Samarth (Chief Business Officer) Option Ex 3,000 1.81 5,430
2017-04-20 Dylan-hyde Tyler (Chief Legal Officer) Sale 2,937 17.37 51,024
2017-04-20 Kulkarni Samarth (Chief Business Officer) Sale 2,800 17.36 48,621
2017-04-20 Kulkarni Samarth (Chief Business Officer) Option Ex 2,800 1.81 5,068
2017-04-20 Novak Rodger (Chief Executive Officer) Sale 2,294 17.37 39,851
2017-04-20 Novak Rodger (Chief Executive Officer) Option Ex 2,294 1.81 4,152
2017-04-19 Dylan-hyde Tyler (Chief Legal Officer) Sale 7,240 18.04 130,587
2017-04-19 Kulkarni Samarth (Chief Business Officer) Sale 7,258 18.04 130,927
2017-04-19 Kulkarni Samarth (Chief Business Officer) Option Ex 7,258 1.81 13,136
2017-04-19 Novak Rodger (Chief Executive Officer) Sale 47,706 18.09 862,906
2017-04-19 Novak Rodger (Chief Executive Officer) Option Ex 47,706 1.81 86,347
2016-10-24 Lundberg Sven Ante (Chief Scientific Officer) Buy 400 14.00 5,600
2016-10-24 Woiwode Thomas (Director) Buy 161,000 14.00 2,254,000
2016-10-24 George Simeon Buy 66,500 14.00 931,000
2016-10-24 Bolzon Bradley J Phd (Director) Buy 161,000 14.00 2,254,000
2016-10-24 Emster Kurt Von (Director) Buy 56,000 14.00 784,000
2016-10-24 Glaxosmithkline Plc Buy 66,500 14.00 931,000
2016-10-24 Celgene Corp /de/ (10% Owner) Buy 800,150 14.00 11,202,100

Insider trading activities including stock purchases, stock sales, and option exercises of CRSP listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Crispr Therapeutics Ag (symbol CRSP, CIK number 1674416) see the Securities and Exchange Commission (SEC) website.